Delonix Bioworks tackles the global challenge of S. aureus infections by leveraging synthetic biology tools and innovative mechanisms of action. Their approach offers a promising solution to combat antibiotic-resistant bacteria, with preclinical proof-of-concept data demonstrating exceptional potential in addressing this critical healthcare issue.